E-LIB Suche - Ergebnisse für: Popplewell, Leslie

1

Real‐world experience of axicabtagene ciloleucel, a CD19‐di..:

Othman, Tamer ; Baird, John H. ; Pak, Stacy...
British Journal of Haematology. 205 (2024) 1 - p. 368-372 , 2024

Link: https://doi.org/10.1111/..

2

Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in R..:

Kambhampati, Swetha ; Mei, Matthew G. ; Chen, Lu...
Clinical Lymphoma Myeloma and Leukemia. , 2024

Link: https://doi.org/10.1016/..

3

Durable Efficacy and Manageable Safety in Patients Age ≥75 ..:

Landsburg, Daniel J. ; Heim, Michael ; Moskop, Amy...
Transplantation and Cellular Therapy. 30 (2024) 2 - p. S187-S188 , 2024

Link: https://doi.org/10.1016/..

4

Durable response after tisagenlecleucel in adults with rela..:

Dreyling, Martin ; Fowler, Nathan Hale ; Dickinson, Michael...
Blood. 143 (2024) 17 - p. 1713-1725 , 2024

Link: https://doi.org/10.1182/..

5

Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refracto..:

Mei, Matthew ; Tsai, Ni-Chun ; Palmer, Joycelynne...
Clinical Lymphoma Myeloma and Leukemia. 24 (2024) 8 - p. 537-542 , 2024

Link: https://doi.org/10.1016/..

6

Real-World Tisagenlecleucel Outcomes in Richter-Transformed..:

Shadman, Mazyar ; Frigault, Matthew J. ; Foley, Stephen Ronan...
Transplantation and Cellular Therapy. 30 (2024) 2 - p. S189-S190 , 2024

Link: https://doi.org/10.1016/..

7

Brentuximab vedotin plus cyclophosphamide, doxorubicin, eto..:

Herrera, Alex F ; Zain, Jasmine ; Savage, Kerry J...
The Lancet Haematology. , 2024

Link: https://doi.org/10.1016/..

8

Clinical Outcomes of Patients with Relapsed/Refractory Foll..:

Schuster, Stephen J. ; Fowler, Nathan H. ; Dickinson, Michael...
Transplantation and Cellular Therapy. 30 (2024) 2 - p. S38-S39 , 2024

Link: https://doi.org/10.1016/..

9

Atezolizumab combined with immunogenic salvage chemoimmunot..:

Othman, Tamer ; Frankel, Paul ; Allen, Pamela...
Haematologica. , 2024

Link: https://doi.org/10.3324/..

10

Bendamustine lymphodepletion is a well‐tolerated alternativ..:

Ong, Shin Yeu ; Pak, Stacy ; Mei, Matthew...
American Journal of Hematology. 98 (2023) 11 - p. 1751-1761 , 2023

Link: https://doi.org/10.1002/..

11

CT-564 ELARA Trial Update: Long-Term Clinical Outcomes and ..:

Fowler, Nathan ; Dreyling, Martin ; Dickinson, Michael...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S534-S535 , 2023

Link: https://doi.org/10.1016/..

12

P1125: DURABLES RESPONSES ACHIEVED WITH ANTI-CD19 ALLOGENEI..:

Munoz, Javier ; Locke, Frederick ; Lekakis, Lazaros...
HemaSphere. 7 (2023) S3 - p. e8808264 , 2023

Link: https://doi.org/10.1097/..

13

A phase 1 first‐in‐human study of GS‐0189, an anti‐signal r..:

Narkhede, Mayur ; Bartlett, Nancy L. ; Ibrahimi, Sami...
eJHaem. 4 (2023) 2 - p. 370-380 , 2023

Link: https://doi.org/10.1002/..

14

S223: REAL-WORLD EARLY OUTCOMES OF AXICABTAGENE CILOLEUCEL ..:

Jacobson, Caron ; Hemmer, Michael T. ; Hu, Zhen-Huan...
HemaSphere. 7 (2023) S3 - p. e31464ce , 2023

Link: https://doi.org/10.1097/..

15

Results from a phase I trial of pembrolizumab plus vorinost..:

Godfrey, James ; Mei, Matthew ; Chen, Lu...
Haematologica. 109 (2023) 2 - p. 533-542 , 2023

Link: https://doi.org/10.3324/..